Implications of Aggressive Therapy in PAH Without Comorbidities
b'Host: Rajan Saggar, MD
\\n\\n\\n \\n
The 2022 ERS/ESC revision of guidelines for diagnosis, risk assessment, and treatment of all forms of pulmonary hypertension (PH) has created some "wrinkles" that may affect how practitioners approach PH patient management. This program explores some of the more controversial aspects of the new guidelines and, using case examples, considers how the new guidelines might affect PH patient management.
'